The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELAN | +70.93% | -31.04% | -7.16% | -40% |
| S&P | +14.5% | +93.32% | +14.09% | +129% |
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.
Investors were cheered not only by the company's third-quarter double beat, but by guidance that was revised for the better.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.24B | 4.8% |
| Gross Profit | $577.00M | 3.4% |
| Gross Margin | 46.49% | -0.6% |
| Market Cap | $7.09B | -0.5% |
| Market Cap / Employee | $0.75M | 0.0% |
| Employees | 9.4K | -3.6% |
| Net Income | $11.00M | 122.0% |
| EBITDA | $254.00M | -8.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $539.00M | 29.6% |
| Accounts Receivable | $989.00M | -1.0% |
| Inventory | 1.7K | 3.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.15B | -24.1% |
| Short Term Debt | $61.00M | -71.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.16% | 11.6% |
| Return On Invested Capital | -3.01% | 0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $180.00M | 8.4% |
| Operating Free Cash Flow | $237.00M | 18.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 35.95 | 17.85 | 14.01 | 16.36 | - |
| Price to Book | 1.22 | 0.92 | 0.85 | 1.12 | -5.21% |
| Price to Sales | 1.64 | 1.35 | 1.18 | 1.59 | 0.32% |
| Price to Tangible Book Value | -2.86 | -2.83 | -2.60 | -3.96 | 45.53% |
| Price to Free Cash Flow TTM | 19.24 | 15.20 | 15.10 | 19.78 | 17.90% |
| Enterprise Value to EBITDA | 67.75 | 57.93 | 32.44 | 42.56 | -4.85% |
| Free Cash Flow Yield | 5.2% | 6.6% | 6.6% | 5.1% | -15.18% |
| Return on Equity | 3.2% | 5.5% | 6.0% | 6.8% | -136.34% |
| Total Debt | $4.36B | $4.44B | $4.40B | $4.21B | -25.85% |
ELAN earnings call for the period ending December 31, 2024.
ELAN earnings call for the period ending September 30, 2024.
ELAN earnings call for the period ending June 30, 2024.
ELAN earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
